Billionaire John Paulson’s 2023 Portfolio: Top 5 Stock Picks

In this article, we discuss the top 5 stock picks from John Paulson’s latest portfolio. If you want to read our discussion on Paulson’s economic outlook, go directly to Billionaire John Paulson’s 2023 Portfolio: Top 15 Stock Picks.

5. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Number of Hedge Fund Holders: 75

John Paulson’s Paulson & Co.’s Holdings: $109,140,000

Percentage of John Paulson’s Paulson & Co.’s Portfolio: 9.07%

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) or more commonly known as Horizon Therapeutics, is a Dublin, Ireland-based biopharmaceutical company that focuses on developing and commercializing medicines for rare and rheumatic diseases. The company is in the middle of a $27.8 billion takeover by Amgen Inc. (NASDAQ:AMGN). However, the deal has hit a roadblock as the US Federal Trade Commission (FTC) is expected to file a lawsuit highlighting that the proposed deal would undermine competition in the industry.

Renaissance Investment Management shared its outlook on  Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in its Q4 2022 investor letter. Here’s what the firm said:

“In the fourth quarter, Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) was our strongest performing stock, returning 83.9%. The company announced that it is being acquired by Amgen (AMGN) in a deal valued at approximately $26.4 billion. Horizon possesses several core assets, including Tepezza, the de facto drug treatment for thyroid eye disease, a solid mix of other medications, and a robust drug pipeline that should help Amgen offset potential revenue losses when several of its large drugs come off patent protection in upcoming years.”